An observational study in Hip Fractures (i.e. Femoral Neck or Intertrochanteric Hip Fractures), sponsored by Beijing Hospital. Recruiting at 1 site in China. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Beijing Hospital · Observational
To address the difficulties and problems currently facing large-scale clinical cohort studies in China, and on the basis of the existing project "Construction of Clinical Registration Database and Risk Assessment System for Osteoporosis and Osteoarthritis" under the National Key R\&D Program of the Ministry of Science and Technology, this project aims to target elderly hip fracture-an international public health issue-by collaborating with 38 hospitals across the country to jointly establish the largest specialized cohort for elderly hip fracture in China, thereby providing a data platform and technical support for multicenter clinical cohort studies on elderly hip fracture.
Hip fracture inpatients at grade-A tertiary hospitals across China
Inclusion Criteria:1: The subjects are of Chinese nationality.
2: The subject is 60 years of age or older (including the boundary value)
3:The subject has been diagnosed with hip fracture by imaging, including femoral neck fracture, intertrochanteric fracture of femur, and subtrochanteric fracture of femur
4: Patients who were hospitalized for hip fracture treatment (surgical or conservative) after September 1, 2022
5: The subject can fully understand and sign the informed consent form.
-
Exclusion Criteria:1: Pathological fractures caused by primary or metastatic tumors of bone or bone developmental disorders
2: Patients with peri-implant fractures or polytrauma (multiple injuries resulting from a single traumatic event in which two or more anatomical sites in the body are severely injured, with one of them being severely injured even in the absence of the traumatic event also posing a life-threatening risk)
3: Subjects who, in the opinion of the investigator, are not eligible for enrollment in the study.
-
A cohort of elderly patients with hip fracture
death
Post-hip fracture mortality (yes/no)
Time frame: Six months, one year, and two years after hip fracture
Clavien-Dindo classification of complications
Clavien-Dindo classification of complications
Time frame: Six months, one year, and two years after hip fracture
Conservative treatment status for patients managed non-surgically
Conservative treatment status for patients managed non-surgically
Time frame: Six months, one year, and two years after hip fracture
Imaging data
Imaging data
Time frame: one day，Six months, one year, and two years after hip fracture
Other new adverse events
Other new adverse events
Time frame: Six months, one year, and two years after hip fracture
Place of residence at follow-up.
Place of residence at follow-up.
Time frame: Six months, one year, and two years after hip fracture
Post-hospital care
Post-hospital care
Time frame: Six months, one year, and two years after hip fracture
Anti-osteoporosis treatment status
Anti-osteoporosis treatment status
Time frame: Six months, one year, and two years after hip fracture
EQ-5D Quality of Life score
EQ-5D Quality of Life score
Time frame: Six months, one year, and two years after hip fracture
Time to discontinuation of strict bed rest
Time to discontinuation of strict bed rest
Time frame: Six months, one year, and two years after hip fracture
Refracture event
Refracture event
Time frame: Six months, one year, and two years after hip fracture
FAC Functional Walking Scale
FAC Functional Walking Scale
Time frame: Six months, one year, and two years after hip fracture
Plan to share: Yes — De-identified individual participant data (IPD) from this nationwide multicenter prospective cohort of elderly patients with hip fracture will be shared. The shared dataset includes: (1) demographic and baseline characteristics (age, sex, comorbidities, frailty and functional status); (2) injury and treatment details (fracture type, surgical procedure, anesthesia method, timing of surgery); (3) perioperative management data (blood transfusion, rehabilitation); and (4) outcome data at each follow-up time point (mortality, complications, reoperation, functional scores such as FAC or EQ-5D, and quality of life). All direct identifiers (name, ID number, phone, address, hospital record number) will be removed before sharing. Data from individual centers will be pooled after harmonization across sites.
Supporting information: Study protocol, Sap, Icf, Csr
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beijing Hospital